13 No source found (not proven false)
Russian bioregulator peptides act as epigenetic modifiers that bind to DNA grooves, and Pinealon shuttles heat shock proteins with androgen receptors.
"The Russian peptides are all epigenetic modifiers that they bind to the groove of the DNA in certain spots that either open up or close the chromatin to certain areas of genetic expression... So like pinealon that we've talked about shuttles heat shock proteins with androgen receptors." (said at 0:05:20)
The claim bundles two distinct assertions. First, preclinical and in vitro literature (primarily from Russian researchers such as Khavinson and colleagues) suggests that synthetic ultrashort 'bioregulator' peptides (including Pinealon/EDR, Epitalon/AEDG, etc.) can penetrate cell nuclei, interact directly with DNA sequences/grooves, and modulate gene expression and epigenetic marks. Second, the assertion that 'Pinealon shuttles heat shock proteins with androgen receptors' has no published scientific record or validation in the biomedical literature. While heat shock proteins (such as HSP90 and HSP70) are known endogenous chaperones that interact with the androgen receptor in human physiology, no published studies demonstrate that Pinealon acts as a shuttle for heat shock proteins and androgen receptors.
- partial: Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in v… (Biochemistry. Biokhimiia 2011) · cited 65x in the literature
"Judging from corresponding constants of the fluorescence quenching, the epithalon, pinealon, and bronchogen (Ala-Glu-Asp-Leu) bind preferentially with deoxyribooligonucleotides containing CNG sequence (CNG sites are targets for cytosine DNA methylation in eukaryotes)... The site-specific interactions of peptides with DNA can control epigenetically the cell genetic functions" (abstract, results, passage verified)
pubmedfull study (doi) - context: EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involv… (Molecules (Basel, Switzerland) 2020) · cited 13x in the literature
"The EDR peptide (Glu-Asp-Arg) has been previously established to possess neuroprotective properties. It activates gene expression and synthesis of proteins, involved in maintaining the neuronal functional activity, and reduces the intensity of their apoptosis in in vitro and in vivo studies." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Peptide Regulation of Gene Expression: A Systematic Review. (Molecules (Basel, Switzerland) 2021) · cited 43x in the literature
"Short peptides, consisting of 2-7 amino acid residues, can penetrate into the nuclei and nucleoli of cells and interact with the nucleosome, the histone proteins, and both single- and double-stranded DNA... Peptides can regulate the status of DNA methylation, which is an epigenetic mechanism for the activation or repression of genes in both the normal condition, as well as in cases of pathology and senescence." (abstract, results, passage verified)
pubmedfull study (doi)
A Croatian clinical trial evaluated rectal enemas of BPC-157 at doses up to 80 milligrams in patients with ulcerative colitis, finding no adverse events in phase 1 and absence of systemic drug levels in the blood.
"There was two very small phase 1 and phase 2 trials on rectal BPC enemas in the early 2000s from that same Croatian group... And they used enemas of BPC up to like 80 milligrams, which is much more than people would take... The phase 1 trial showed no adverse effects. And they didn't even have BPC in the systemic system too." (said at 0:20:05)
While review articles by the Croatian research group (Sikiric et al.) reference phase 1 and phase 2 clinical trials of BPC-157 (PL 14736) in inflammatory bowel disease and report an absence of side effects, full primary peer-reviewed clinical trial reports documenting rectal enema administration of doses up to 80 mg, complete phase 1 safety outcomes, and pharmacokinetic data demonstrating absence of systemic blood levels have not been published in indexed medical literature.
- partial: Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. (Current medicinal chemistry 2012) · cited 51x in the literature
"BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect." (abstract, results, passage verified)
pubmedfull study (doi) - context: Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. (Current reviews in musculoskeletal medicine 2025) · cited 19x in the literature
"Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking." (abstract, results, passage verified)
pubmedfull study (doi)
In a melanoma cell line model, BPC-157 decreases VEGF expression.
"Now BPC-157 is not a uniform angiogenesis upregulator. In some models it decreases VEGF in a melanoma model, a cell line." (said at 0:47:51)
No published in vitro or in vivo studies were identified examining the effect of BPC-157 on VEGF expression in a melanoma cell line model. While reviews discussing BPC-157 describe its context-dependent modulation of angiogenesis and nitric oxide signaling across various tissue repair models, specific experimental evidence demonstrating downregulation of VEGF by BPC-157 in melanoma cells remains unlocated in the published peer-reviewed literature.
In a study by Khavinson, athletes given Pinealon were able to maintain performance following maximal exhaustion during training compared to placebo.
"So he studied this compound on athletes and he would have them do their training session, go to exhaustion, and then do a test afterwards. And there's two groups: Pinealon and the placebo. The Pinealon group could keep their performance up despite being maximally exhausted from their training." (said at 1:14:46)
No published clinical trial or study in the indexed medical literature was identified where Vladimir Khavinson (or colleagues) administered Pinealon (the tripeptide Glu-Asp-Arg / EDR) to athletes in a placebo-controlled trial evaluating performance maintenance after maximal exhaustion. While Khavinson and colleagues have published extensively on Pinealon's neuroprotective, antioxidant, and geroprotective effects in cell cultures, animal models, and elderly human cohorts, the specific athlete exhaustion trial described by the speaker could not be verified in peer-reviewed scientific databases.
Pinealon can cause a reduction in blood glucose and HbA1c via activation of PPAR-alpha and PPAR-gamma.
"Some will have a little drop in blood sugar because it activates PPAR-alpha, PPAR-gamma. So it'll have positive metabolic effects. So that's something to keep an eye out. And in some people even had their A1Cs drop." (said at 1:17:10)
No published studies in PubMed or Europe PMC were found demonstrating that Pinealon (the synthetic tripeptide Glu-Asp-Arg / EDR) activates PPAR-alpha or PPAR-gamma, reduces blood glucose, or lowers HbA1c in humans or animal models. While Pinealon has been investigated in limited preclinical and Russian literature primarily for neuroprotective, antioxidant, and geroprotective effects, the claimed mechanism involving PPAR activation and glycemic endpoints is unverified in the biomedical literature.
Five days of total darkness significantly increases retinal melanopsin levels in animal models.
"Because we know that in animal studies, five days of pure darkness dramatically increases the amount of melanopsin in the retina." (said at 1:27:56)
A targeted literature search did not identify animal studies demonstrating that five days of total/pure darkness dramatically increases retinal melanopsin levels or expression. While light deprivation and exposure to specific wavelengths (such as blue light) are known to modulate melanopsin (Opn4) mRNA and protein immunoreactivity in rodents (e.g., blue light exposure reduces melanopsin expression, while photoperiods alter daily transcript profiles), no published record matching the specific claim of a dramatic increase following five days of pure darkness was located. This does not prove the claim false, but it remains unverified in the published literature.
- context: Daily profile in melanopsin transcripts depends on seasonal lighting conditions in the rat… (Journal of neuroendocrinology 2007) · cited 35x in the literature
"Under constant darkness, the rhythm of mRNA was abolished for melanopsin, but persisted for AA-NAT whereas, under constant light, the rhythm of mRNA was abolished for both genes. Our findings suggest that, in contrast to the AA-NAT gene, the daily and photoperiod-dependent regulation of the melanopsin gene does not rely on a circadian oscillator but is directly illumination-dependent." (abstract, results, passage verified)
pubmedfull study (doi) - context: Low-Intensity Blue Light Exposure Reduces Melanopsin Expression in Intrinsically Photosens… (Cells 2023) · cited 11x in the literature
"LTE reduced the length of Opn4-positive ipRGC dendrites ( p = 0.03) and decreased Opn4-immunoreactivity in ipRGC outer stratifying dendrites." (abstract, results, passage verified)
pubmedfull study (doi)
In Khavinson's research, Epitalon administration increased the expression of clock genes in peripheral lymphocytes and increased morning cortisol levels.
"So in Khavinson's work, he's found that it will increase the expression of the different clock genes. So in like, you know, lymphocytes that he'll measure in peripheral tissues, he'll notice that the clock genes actually change. So in a more rhythmic pattern, he'll notice that morning cortisol is higher." (said at 1:22:55)
A search of Vladimir Khavinson's published literature found no studies demonstrating that Epitalon (or Epithalon/Epithalamin) increases the expression of clock genes in human or animal peripheral lymphocytes. Khavinson's group did publish research in senescent female rhesus monkeys (Macaca mulatta) showing that Epitalon stimulated evening melatonin production and helped normalize the circadian rhythm of cortisol secretion (PMID 11524632), but the specific claim regarding clock gene expression in peripheral lymphocytes is not documented in the peer-reviewed indexed literature.
A Nature study using MRI found that individuals with higher thymic scores had reduced mortality from cardiovascular disease and cancer.
"There's a Nature paper uh 2026 just came out that looked at cardiovascular disease and cancer mortality and all these different metrics, that they did MRIs of people, and and the people that had the higher thymic scores had less mortality across every single one of these conditions." (said at 1:33:39)
A targeted search of PubMed and Europe PMC found no published study in Nature (or other peer-reviewed journals) evaluating MRI-derived thymic scores in relation to cardiovascular disease, cancer mortality, or all-cause mortality. While prominent observational studies (such as a 2023 NEJM study by Kooshesh et al.) have linked surgical removal of the thymus (thymectomy) to increased risks of cancer, autoimmune disease, and all-cause mortality, no specific Nature study establishing an MRI-based 'thymic score' predictive of reduced mortality across these specific conditions was identified.
Pinealon is sold over the counter in pharmacies as a dietary supplement in countries such as Russia, Kazakhstan, and Ukraine.
"And pinealon is a supplement you can find in Kazakhstan and Russia and Ukraine, wherever, all these different countries, over the counter in pharmacies." (said at 1:44:11)
Biomedical literature indexed in PubMed confirms that Pinealon (the synthetic tripeptide Glu-Asp-Arg, or EDR) is a peptide bioregulator ('cytogen') developed and investigated in Russia for neuroprotective and geroprotective uses in occupational and clinical cohorts. However, the specific commercial and regulatory claim that Pinealon is sold over the counter in pharmacies as a dietary supplement across Russia, Kazakhstan, and Ukraine cannot be verified through standard biomedical research databases, as peer-reviewed publications do not track pharmacy retail and regulatory classifications in these countries. This lack of indexing does not mean the claim is false.
In animal studies, injecting GHK-Cu at a site distant from a surgical incision accelerates skin wound healing.
"So similar to the BPC, they would, you know, cut rats open, inject GHK copper in a different site, and they'd get faster wound repair of the skin tissue from injecting this." (said at 1:52:56)
While animal research has evaluated GHK-Cu for tissue repair (for example, local injection into subcutaneous wound chambers in rats or topical preparations), no published studies were located demonstrating that injecting GHK-Cu at a site distant from a surgical incision accelerates skin wound healing. Most in vivo wound healing models evaluate direct local application or wound chamber administration rather than distant-site systemic delivery.
Tesamorelin combined with ipamorelin can increase IGF-1 levels into the 380s or 390s ng/mL.
"Tesamorelin, especially when combined with ipamorelin... Those two together can create a giant growth hormone response where your IGF-1 is in the 380s, 390s. Um, so that's quite high, like puberty levels of IGF-1" (said at 2:13:10)
No published clinical studies have evaluated the combination of tesamorelin and ipamorelin or demonstrated that this specific combination elevates IGF-1 levels to 380-390 ng/mL. Narrative reviews on performance-enhancing and off-label peptides note that while GHRH analogues (such as tesamorelin) and GH secretagogues (such as ipamorelin) are frequently combined in gray-market or self-administration protocols to stimulate the GH-IGF-1 axis, clinical trial data for such stacking practices and their resulting IGF-1 levels are lacking.
- context: Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injur… (Sports medicine (Auckland, N.Z.) 2026)
"While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (follistatin-344), GHK-Cu (glycyl-L-histidyl-L-lysine copper), ipamorelin, MOTS-C (mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (elamipretide), tesamorelin (Egrifta), Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment)." (abstract, results, passage verified)
pubmedfull study (doi) - context: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging… (Frontiers in endocrinology 2026)
"The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagogues (GHS; e.g., growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing peptide-6 (GHRP-6), hexarelin, ipamorelin)... Given the absence of regulatory approval for physique- or performance-related indications and the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains, clinicians increasingly require a pragmatic framework to interpret symptoms and laboratory abnormalities in patients using these compounds." (abstract, results, passage verified)
pubmedfull study (doi)
Retatrutide contains 39 amino acids.
"retatrutide has 39 amino acids." (said at 2:35:00)
While retatrutide (LY3437943) is biochemically characterized as a 39-amino-acid peptide triple agonist at the GIP, GLP-1, and glucagon receptors, the specific peptide length of 39 amino acids was not explicitly stated in the abstracts of the retrieved records, although retatrutide was confirmed to be a synthetic peptide agonist.
To be classified as a biologic under regulatory standards, a molecule must contain more than 40 amino acids.
"To be a biologic, you have to be above 40 amino acids." (said at 2:35:03)
No retrieved publication abstract contained the specific regulatory text regarding the amino acid threshold. Under United States Food and Drug Administration (FDA) regulations following the Biologics Price Competition and Innovation Act (BPCI Act) and subsequent FDA rulemakings (21 CFR Part 600), the 40 amino acid threshold is used specifically to distinguish 'peptides' (40 or fewer amino acids, typically regulated as small-molecule drugs under the FD&C Act) from 'proteins' (greater than 40 amino acids, regulated as biological products under the Public Health Service Act). However, biologics also encompass many non-protein entities (such as vaccines, blood components, and gene/cell therapies), making the claim that a molecule 'must contain more than 40 amino acids' to be a biologic an imprecise description of the broader category.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.